查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1601067

微生物组治疗市场：副产品、治疗领域、配方、来源、最终用途、分销管道 - 2025-2030 年全球预测

Microbiome Therapeutics Market by Products, Therapeutic Area, Formulation, Source, End-use, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年微生物组治疗市值为9.8802亿美元，预计到2024年将达到11.1894亿美元，复合年增长率为14.45%，预计到2030年将达到25.4245亿美元。

微生物组疗法是指利用活生物体和有针对性的营养策略来调节人类肠道微生物组以解决各种健康问题的治疗方法。这些治疗方法对于治疗胃肠道疾病、代谢症候群、自体免疫疾病等至关重要，并且有可能扩展到心理健康和肿瘤学领域。对微生物组疗法的需求源于人们对微生物组在维持健康和相关疾病增加中的重要作用的日益了解。最终用途涵盖许多领域，包括製药、机能性食品和生物技术。主要成长动力包括基因序列测定和诊断技术的进步、製药公司投资的增加以及消费者对整体健康解决方案的兴趣增加。随着监管机构采用以微生物为基础的解决方案框架，为创新产品提供更顺畅的进入，一个显着的机会将会出现。为了利用这些机会，相关人员应促进新研发项目的产学合作，并利用适应性试验设计来加速临床试验过程。然而，严格的监管环境、人类微生物与宿主相互作用的复杂性以及高产品开发成本等挑战可能会阻碍市场开拓。此外，由于微生物组研究标准化有限，产品功效可能不一致。克服这些障碍需要在个人化医疗方面进行深入创新，并开发强大且具成本效益的微生物组调控和分析平台。对开拓的细菌菌株和合成生物学的研究有可能带来突破。市场正在从小众发展为主流，这反映在创业投资兴趣和策略伙伴关係关係的增加上，需要相关人员的敏捷性和远见。因此，投资者和开发商将重点放在与老龄化相关的微生物组干预和肠脑轴治疗等领域，以在快速扩张的微生物组治疗领域中保持竞争力和相关性。

主要市场统计
基准年[2023] 98802万美元
预测年份 [2024] 111,894 万美元
预测年份 [2030] 25.4245亿美元
复合年增长率（%） 14.45%

市场动态：揭示快速发展的微生物组治疗市场的关键市场洞察

微生物组治疗市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 与文明病盛行率增加
    • 微生物组研究和商业化的政府措施和资助
  • 市场限制因素
    • 微生物组疗法产品回想的潜在风险
  • 市场机会
    • 使用微生物组疗法管理女性荷尔蒙和生殖健康
    • 利用人工智慧扩大微生物组疗法的投资
  • 市场挑战
    • 与治疗中微生物组资料收集和使用相关的伦理和隐私问题

波特的五力：驾驭微生物组治疗市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解微生物组治疗市场的外部影响

外部宏观环境因素在塑造微生物组治疗市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解微生物组治疗市场的竞争格局

对微生物组治疗市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示自己的竞争定位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵微生物治疗市场供应商的绩效评估

FPNV 定位矩阵是评估微生物组治疗市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，规划微生物组治疗市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，微生物组治疗市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 与文明病盛行率增加
      • 政府对微生物组研究和商业化的承诺和资助
    • 抑制因素
      • 微生物组疗法产品回想的潜在风险
    • 机会
      • 利用微生物疗法促进女性荷尔蒙和生殖健康
      • 增加对基于人工智慧的微生物组治疗的投资
    • 任务
      • 与微生物组资料的收集和治疗使用相关的道德和隐私问题
  • 市场区隔分析
    • 产品：对慢性病针对性介入的微生物组疗法的需求不断增长
    • 治疗领域：自体免疫疾病对微生物组疗法的需求不断增加，以减少发炎和调节免疫反应
    • 製剂：解决胃肠道疾病的口服製剂需求增加
    • 资料来源：正在进行的利用动物微生物组来了解肠脑轴和免疫调节的研究
    • 最终用途：用于学术创新的微生物组疗法的不断发展的前景
    • 分销管道：微生物组疗法越来越多地透过线上管道分销。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章微生物组治疗市场：副产品

  • 粪便微生物移植
  • 活体生物疗法
  • 微生物医学
  • 微生物生态系疗法
  • 益生菌和益生元

第 7 章按治疗领域分類的微生物组治疗市场

  • 自体免疫疾病
  • 癌症
  • 胃肠道疾病
  • 感染疾病
  • 代谢紊乱
  • 神经系统疾病

第八章按处方分類的微生物组治疗市场

  • 口服
  • 话题

第 9 章微生物组治疗市场：依来源分类

  • 动物微生物组
  • 环境微生物组
  • 人类微生物组

第10章微生物组治疗市场：依最终用途

  • 学术/研究机构
  • 医院/诊所

第十一章微生物组治疗市场：按分销管道

  • 离线
    • 医院药房
    • 零售药房
  • 网路药房

第十二章美洲微生物组治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十三章亚太微生物组治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第14章欧洲、中东和非洲的微生物组治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十五章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Nexilico 和 Siolta Therapeutics 已达成合作，利用先进的微生物组疗法来推进婴儿 NEC 的治疗。
    • Metagen Therapeutics 与 JSR Corporation 合作在日本建立 FMT 药物生产设施
    • Seed Health 在全国 Target 商店推出益生菌，扩大零售业务
    • Pendulum Therapeutics 和 BiomeSense 宣布进行一项微生物组研究，使用 GutLab 系统持续监测 Akkermansia muciniphila。
    • Canvas Biosciences 融资 1250 万美元，用于推进基于微生物组的免疫肿瘤治疗
    • Biolog, Inc. 推出 PreBioM微孔盘来推进肠道微生物群的表征。
    • Ceres Therapeutics 与雀巢健康科学合作，加强微生物组治疗组合
    • Nature Awards 与 Seed Health 合作推出微生物组加速器解决方案
    • Ceres Therapeutics 加强 VOWST 并实现 SER-155 的 FDA 快速通道。
    • Ferring BV 与 PharmaBiome 合作开发以微生物组为基础的胃肠道疾病治疗方法
    • Persephone Biosciences 和 Ginkgo Bioworks 合作增强拟桿菌工程以促进治疗开发
    • 创新团队透过与微生物疗法 MaaT Pharma 合作扩大规模
  • 战略分析和建议
    • 恩特罗姆公司
    • XBiome有限公司
    • 辉凌公司
    • 谷神星医药科技股份有限公司

公司名单

  • Alveolus Bio, Inc. by ResBiotic
  • AOBiome LLC
  • Assembly Biosciences, Inc.
  • Axial Therapeutics, Inc.
  • BioGaia AB
  • BiomeBank
  • EnteroBiotix Ltd
  • Enterome SA
  • Ferring BV
  • Intralytix, Inc.
  • Kanvas Biosciences
  • Locus Biosciences, Inc.
  • MaaT Pharma SA
  • Microba Life Sciences Limited
  • Microbiotica Ltd.
  • MRM Health NV
  • NuBiyota
  • Osel, Inc.
  • Pendulum Therapeutics
  • PharmaBiome AG
  • Pylum Biosciences
  • Seres Therapeutics, Inc.
  • Servatus Limited
  • Siolta Therapeutics
  • Theriva Biologics, Inc.
  • Vedanta Biosciences, Inc.
  • Viome Life Sciences, Inc. by BlueDot LLC
  • Xbiome Co. Ltd.
Product Code: MRR-ED54C46E807C

The Microbiome Therapeutics Market was valued at USD 988.02 million in 2023, expected to reach USD 1,118.94 million in 2024, and is projected to grow at a CAGR of 14.45%, to USD 2,542.45 million by 2030.

Microbiome therapeutics refer to treatments focused on modulating the human gut microbiota to address various health issues, utilizing live organisms or targeted nutritional strategies. These therapies are pivotal in treating conditions like gastrointestinal disorders, metabolic syndromes, and autoimmune diseases, with potential extensions into mental health and oncology. The necessity of microbiome therapeutics emerges from an increasing understanding of the microbiota's integral role in maintaining health, coupled with growing incidences of related ailments. Applications range from drugs to dietary interventions and supplements, and the end-use spans numerous sectors including pharmaceuticals, functional foods, and biotechnology. Key growth drivers include advancements in genetic sequencing and diagnostic technologies, increased investment from pharmaceutical companies, and a heightened consumer focus on holistic health solutions. Noteworthy opportunities arise from regulatory agencies adopting frameworks for microbiome-based solutions, enabling smoother entry for innovative products. To harness these opportunities, stakeholders should foster collaborations between academia and industry for novel R&D ventures and expedite clinical trial processes by leveraging adaptive trial designs. However, challenges such as stringent regulatory landscapes, the complexity of human microbiota-host interactions, and the high cost of product development can impede market progress. Moreover, limited standardization in microbiome research can lead to inconsistent product efficacy. Overcoming these barriers requires focused innovation in personalized medicine and development of robust, cost-effective platforms for microbiome modulation and analysis. Research into unexplored strains and synthetic biology holds potential for driving breakthroughs. The market is evolving from niche to mainstream, as reflected in growing venture capital interest and strategic partnerships, necessitating agility and foresight from stakeholders. Investors and developers should thus concentrate on areas like age-related microbiome interventions and gut-brain axis therapies to stay competitive and relevant in the fast-expanding microbiome therapeutics arena.

KEY MARKET STATISTICS
Base Year [2023] USD 988.02 million
Estimated Year [2024] USD 1,118.94 million
Forecast Year [2030] USD 2,542.45 million
CAGR (%) 14.45%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Microbiome Therapeutics Market

The Microbiome Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increase in the prevalence of lifestyle-associated diseases
    • Government initiatives and funding for microbiome research and commercialization
  • Market Restraints
    • Potential risk of product recalls in microbiome therapeutics
  • Market Opportunities
    • Leveraging microbiome therapeutics for hormonal and reproductive health of women
    • Growing investment in AI-driven microbiome-based therapeutics
  • Market Challenges
    • Ethical and privacy concerns linked with microbiome data collection and usage in treatments

Porter's Five Forces: A Strategic Tool for Navigating the Microbiome Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Microbiome Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Microbiome Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Microbiome Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Microbiome Therapeutics Market

A detailed market share analysis in the Microbiome Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Microbiome Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Microbiome Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Microbiome Therapeutics Market

A strategic analysis of the Microbiome Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Microbiome Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Alveolus Bio, Inc. by ResBiotic, AOBiome LLC, Assembly Biosciences, Inc., Axial Therapeutics, Inc., BioGaia AB, BiomeBank, EnteroBiotix Ltd, Enterome SA, Ferring B.V., Intralytix, Inc., Kanvas Biosciences, Locus Biosciences, Inc., MaaT Pharma SA, Microba Life Sciences Limited, Microbiotica Ltd., MRM Health NV, NuBiyota, Osel, Inc., Pendulum Therapeutics, PharmaBiome AG, Pylum Biosciences, Seres Therapeutics, Inc., Servatus Limited, Siolta Therapeutics, Theriva Biologics, Inc., Vedanta Biosciences, Inc., Viome Life Sciences, Inc. by BlueDot LLC, and Xbiome Co. Ltd..

Market Segmentation & Coverage

This research report categorizes the Microbiome Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Products, market is studied across Fecal Microbiota Transplantation, Live-Biotherapeutics, Microbiome Drugs, Microbiome Ecosystem Therapies, and Probiotics & Prebiotics.
  • Based on Therapeutic Area, market is studied across Autoimmune Diseases, Cancer, Gastrointestinal Disorders, Infectious Diseases, Metabolic Disorders, and Neurological Disorders.
  • Based on Formulation, market is studied across Oral and Topical.
  • Based on Source, market is studied across Animal Microbiome, Environmental Microbiome, and Human Microbiome.
  • Based on End-use, market is studied across Academic & Research Institutions and Hospitals & Clinics.
  • Based on Distribution Channel, market is studied across Offline and Online Pharmacies. The Offline is further studied across Hospital Pharmacies and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increase in the prevalence of lifestyle-associated diseases
      • 5.1.1.2. Government initiatives and funding for microbiome research and commercialization
    • 5.1.2. Restraints
      • 5.1.2.1. Potential risk of product recalls in microbiome therapeutics
    • 5.1.3. Opportunities
      • 5.1.3.1. Leveraging microbiome therapeutics for hormonal and reproductive health of women
      • 5.1.3.2. Growing investment in AI-driven microbiome-based therapeutics
    • 5.1.4. Challenges
      • 5.1.4.1. Ethical and privacy concerns linked with microbiome data collection and usage in treatments
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Products: Rising need of microbiome therapeutics for targeted interventions in chronic diseases
    • 5.2.2. Therapeutic Area: Growing demand of microbiome therapeutics in autoimmune diseases for reducing inflammation and modulating immune responses
    • 5.2.3. Formulation: Growing demand for oral formulations to address gastrointestinal conditions
    • 5.2.4. Source: Ongoing research for the use of animal microbiomes in understanding the gut-brain axis and immune modulation
    • 5.2.5. End-use: The evolving landscape of microbiome therapeutics for academic innovations
    • 5.2.6. Distribution Channel: Thriving microbiome therapeutics distribution through online channels
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Microbiome Therapeutics Market, by Products

  • 6.1. Introduction
  • 6.2. Fecal Microbiota Transplantation
  • 6.3. Live-Biotherapeutics
  • 6.4. Microbiome Drugs
  • 6.5. Microbiome Ecosystem Therapies
  • 6.6. Probiotics & Prebiotics

7. Microbiome Therapeutics Market, by Therapeutic Area

  • 7.1. Introduction
  • 7.2. Autoimmune Diseases
  • 7.3. Cancer
  • 7.4. Gastrointestinal Disorders
  • 7.5. Infectious Diseases
  • 7.6. Metabolic Disorders
  • 7.7. Neurological Disorders

8. Microbiome Therapeutics Market, by Formulation

  • 8.1. Introduction
  • 8.2. Oral
  • 8.3. Topical

9. Microbiome Therapeutics Market, by Source

  • 9.1. Introduction
  • 9.2. Animal Microbiome
  • 9.3. Environmental Microbiome
  • 9.4. Human Microbiome

10. Microbiome Therapeutics Market, by End-use

  • 10.1. Introduction
  • 10.2. Academic & Research Institutions
  • 10.3. Hospitals & Clinics

11. Microbiome Therapeutics Market, by Distribution Channel

  • 11.1. Introduction
  • 11.2. Offline
    • 11.2.1. Hospital Pharmacies
    • 11.2.2. Retail Pharmacies
  • 11.3. Online Pharmacies

12. Americas Microbiome Therapeutics Market

  • 12.1. Introduction
  • 12.2. Argentina
  • 12.3. Brazil
  • 12.4. Canada
  • 12.5. Mexico
  • 12.6. United States

13. Asia-Pacific Microbiome Therapeutics Market

  • 13.1. Introduction
  • 13.2. Australia
  • 13.3. China
  • 13.4. India
  • 13.5. Indonesia
  • 13.6. Japan
  • 13.7. Malaysia
  • 13.8. Philippines
  • 13.9. Singapore
  • 13.10. South Korea
  • 13.11. Taiwan
  • 13.12. Thailand
  • 13.13. Vietnam

14. Europe, Middle East & Africa Microbiome Therapeutics Market

  • 14.1. Introduction
  • 14.2. Denmark
  • 14.3. Egypt
  • 14.4. Finland
  • 14.5. France
  • 14.6. Germany
  • 14.7. Israel
  • 14.8. Italy
  • 14.9. Netherlands
  • 14.10. Nigeria
  • 14.11. Norway
  • 14.12. Poland
  • 14.13. Qatar
  • 14.14. Russia
  • 14.15. Saudi Arabia
  • 14.16. South Africa
  • 14.17. Spain
  • 14.18. Sweden
  • 14.19. Switzerland
  • 14.20. Turkey
  • 14.21. United Arab Emirates
  • 14.22. United Kingdom

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2023
  • 15.2. FPNV Positioning Matrix, 2023
  • 15.3. Competitive Scenario Analysis
    • 15.3.1. Nexilico and Siolta Therapeutics forge collaboration to advance treatments for infant NEC using advanced microbiome therapeutics
    • 15.3.2. Metagen Therapeutics partners with JSR Corporation to establish an FMT drug manufacturing facility in Japan
    • 15.3.3. Seed Health expands retail presence with launch of probiotics in target stores nationwide
    • 15.3.4. Pendulum Therapeutics and BiomeSense unveiled microbiome research with continuous monitoring of Akkermansia muciniphila using GutLab system
    • 15.3.5. Kanvas Biosciences raised USD 12.5 million to progress microbiome-based immuno-oncology therapies
    • 15.3.6. Biolog, Inc. unveiled PreBioM microplates to advance gut microbiome characterization
    • 15.3.7. Seres Therapeutics collaborates with Nestle Health Science to enhance its microbiome therapeutic portfolio
    • 15.3.8. Nature Awards and Seed Health unite to launch microbiome accelerator solutions
    • 15.3.9. Seres Therapeutics enhanced the VOWST and achieved FDA Fast Track for SER-155
    • 15.3.10. Ferring B.V. signs partnership with PharmaBiome for development of microbiome-based therapies for gastrointestinal conditions
    • 15.3.11. Persephone Biosciences and Ginkgo Bioworks collaborate to enhance Bacteroides engineering for therapeutics development
    • 15.3.12. Microbiome Therapeutics Innovation Group expanded by joining hands with MaaT Pharma
  • 15.4. Strategy Analysis & Recommendation
    • 15.4.1. Enterome SA
    • 15.4.2. Xbiome Co. Ltd.
    • 15.4.3. Ferring B.V.
    • 15.4.4. Seres Therapeutics, Inc.

Companies Mentioned

  • 1. Alveolus Bio, Inc. by ResBiotic
  • 2. AOBiome LLC
  • 3. Assembly Biosciences, Inc.
  • 4. Axial Therapeutics, Inc.
  • 5. BioGaia AB
  • 6. BiomeBank
  • 7. EnteroBiotix Ltd
  • 8. Enterome SA
  • 9. Ferring B.V.
  • 10. Intralytix, Inc.
  • 11. Kanvas Biosciences
  • 12. Locus Biosciences, Inc.
  • 13. MaaT Pharma SA
  • 14. Microba Life Sciences Limited
  • 15. Microbiotica Ltd.
  • 16. MRM Health NV
  • 17. NuBiyota
  • 18. Osel, Inc.
  • 19. Pendulum Therapeutics
  • 20. PharmaBiome AG
  • 21. Pylum Biosciences
  • 22. Seres Therapeutics, Inc.
  • 23. Servatus Limited
  • 24. Siolta Therapeutics
  • 25. Theriva Biologics, Inc.
  • 26. Vedanta Biosciences, Inc.
  • 27. Viome Life Sciences, Inc. by BlueDot LLC
  • 28. Xbiome Co. Ltd.

LIST OF FIGURES

  • FIGURE 1. MICROBIOME THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. MICROBIOME THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS MICROBIOME THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. AMERICAS MICROBIOME THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES MICROBIOME THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 21. UNITED STATES MICROBIOME THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC MICROBIOME THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC MICROBIOME THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. MICROBIOME THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 27. MICROBIOME THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. MICROBIOME THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. MICROBIOME THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY FECAL MICROBIOTA TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY LIVE-BIOTHERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY MICROBIOME DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY MICROBIOME ECOSYSTEM THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY PROBIOTICS & PREBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY ANIMAL MICROBIOME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY ENVIRONMENTAL MICROBIOME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY HUMAN MICROBIOME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS MICROBIOME THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 53. BRAZIL MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 54. BRAZIL MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 55. BRAZIL MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 56. BRAZIL MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 58. CANADA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 59. CANADA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 60. CANADA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 61. CANADA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 62. CANADA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 63. CANADA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. CANADA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 65. MEXICO MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 66. MEXICO MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 67. MEXICO MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 68. MEXICO MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 69. MEXICO MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 70. MEXICO MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. MEXICO MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 72. UNITED STATES MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 73. UNITED STATES MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 74. UNITED STATES MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 75. UNITED STATES MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 76. UNITED STATES MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 77. UNITED STATES MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. UNITED STATES MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 79. UNITED STATES MICROBIOME THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC MICROBIOME THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 88. AUSTRALIA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 89. AUSTRALIA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 90. AUSTRALIA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 91. AUSTRALIA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 92. AUSTRALIA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 93. AUSTRALIA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. AUSTRALIA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 95. CHINA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 96. CHINA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 97. CHINA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 98. CHINA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 99. CHINA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 100. CHINA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. CHINA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 102. INDIA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 103. INDIA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 104. INDIA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 105. INDIA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 106. INDIA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 107. INDIA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 108. INDIA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 109. INDONESIA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 110. INDONESIA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 111. INDONESIA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 112. INDONESIA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 113. INDONESIA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 114. INDONESIA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. INDONESIA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 116. JAPAN MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 117. JAPAN MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 118. JAPAN MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 119. JAPAN MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 120. JAPAN MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 121. JAPAN MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. JAPAN MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 123. MALAYSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 124. MALAYSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 125. MALAYSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 126. MALAYSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 127. MALAYSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 128. MALAYSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 129. MALAYSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 130. PHILIPPINES MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 131. PHILIPPINES MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 132. PHILIPPINES MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 133. PHILIPPINES MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 134. PHILIPPINES MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 135. PHILIPPINES MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 136. PHILIPPINES MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 137. SINGAPORE MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 138. SINGAPORE MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 139. SINGAPORE MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 140. SINGAPORE MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 141. SINGAPORE MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 142. SINGAPORE MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 143. SINGAPORE MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 144. SOUTH KOREA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 145. SOUTH KOREA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 146. SOUTH KOREA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 147. SOUTH KOREA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 148. SOUTH KOREA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 149. SOUTH KOREA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 150. SOUTH KOREA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 151. TAIWAN MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 152. TAIWAN MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 153. TAIWAN MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 154. TAIWAN MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 155. TAIWAN MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 156. TAIWAN MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 157. TAIWAN MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 158. THAILAND MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 159. THAILAND MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 160. THAILAND MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 161. THAILAND MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 162. THAILAND MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 163. THAILAND MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 164. THAILAND MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 165. VIETNAM MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 166. VIETNAM MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 167. VIETNAM MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 168. VIETNAM MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 169. VIETNAM MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 170. VIETNAM MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 171. VIETNAM MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 180. DENMARK MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 181. DENMARK MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 182. DENMARK MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 183. DENMARK MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 184. DENMARK MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 185. DENMARK MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 186. DENMARK MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 187. EGYPT MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 188. EGYPT MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 189. EGYPT MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 190. EGYPT MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 191. EGYPT MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 192. EGYPT MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 193. EGYPT MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 194. FINLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 195. FINLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 196. FINLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 197. FINLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 198. FINLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 199. FINLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 200. FINLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 201. FRANCE MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 202. FRANCE MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 203. FRANCE MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 204. FRANCE MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 205. FRANCE MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 206. FRANCE MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 207. FRANCE MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 208. GERMANY MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 209. GERMANY MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 210. GERMANY MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 211. GERMANY MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 212. GERMANY MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 213. GERMANY MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 214. GERMANY MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 215. ISRAEL MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 216. ISRAEL MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 217. ISRAEL MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 218. ISRAEL MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 219. ISRAEL MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 220. ISRAEL MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 221. ISRAEL MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 222. ITALY MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 223. ITALY MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 224. ITALY MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 225. ITALY MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 226. ITALY MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 227. ITALY MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 228. ITALY MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 229. NETHERLANDS MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 230. NETHERLANDS MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 231. NETHERLANDS MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 232. NETHERLANDS MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 233. NETHERLANDS MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 234. NETHERLANDS MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 235. NETHERLANDS MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 236. NIGERIA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 237. NIGERIA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 238. NIGERIA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 239. NIGERIA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 240. NIGERIA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 241. NIGERIA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 242. NIGERIA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 243. NORWAY MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 244. NORWAY MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 245. NORWAY MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 246. NORWAY MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 247. NORWAY MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 248. NORWAY MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 249. NORWAY MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 250. POLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 251. POLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 252. POLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 253. POLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 254. POLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 255. POLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 256. POLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 257. QATAR MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 258. QATAR MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 259. QATAR MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 260. QATAR MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 261. QATAR MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 262. QATAR MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 263. QATAR MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 264. RUSSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 265. RUSSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 266. RUSSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 267. RUSSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 268. RUSSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 269. RUSSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 270. RUSSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 271. SAUDI ARABIA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 272. SAUDI ARABIA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 273. SAUDI ARABIA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 274. SAUDI ARABIA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 275. SAUDI ARABIA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 276. SAUDI ARABIA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 277. SAUDI ARABIA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 278. SOUTH AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 279. SOUTH AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 280. SOUTH AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 281. SOUTH AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 282. SOUTH AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 283. SOUTH AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 284. SOUTH AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 285. SPAIN MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 286. SPAIN MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 287. SPAIN MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 288. SPAIN MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 289. SPAIN MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 290. SPAIN MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 291. SPAIN MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 292. SWEDEN MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 293. SWEDEN MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 294. SWEDEN MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 295. SWEDEN MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 296. SWEDEN MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 297. SWEDEN MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 298. SWEDEN MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 299. SWITZERLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 300. SWITZERLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 301. SWITZERLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 302. SWITZERLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 303. SWITZERLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 304. SWITZERLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 305. SWITZERLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 306. TURKEY MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 307. TURKEY MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 308. TURKEY MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 309. TURKEY MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 310. TURKEY MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 311. TURKEY MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 312. TURKEY MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 313. UNITED ARAB EMIRATES MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 314. UNITED ARAB EMIRATES MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 315. UNITED ARAB EMIRATES MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 316. UNITED ARAB EMIRATES MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 317. UNITED ARAB EMIRATES MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 318. UNITED ARAB EMIRATES MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 319. UNITED ARAB EMIRATES MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 320. UNITED KINGDOM MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 321. UNITED KINGDOM MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 322. UNITED KINGDOM MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 323. UNITED KINGDOM MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 324. UNITED KINGDOM MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 325. UNITED KINGDOM MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 326. UNITED KINGDOM MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 327. MICROBIOME THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 328. MICROBIOME THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023